Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Envisagenics Inc.

Envisagenics is an Artificial Intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders. Envisagenics partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities. Envisagenics also has its own internally developed RNA therapeutic programs. Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute. *


Period Start 2014-04-22 established (s-off)
  Predecessor Cold Spring Harbor Laboratory (CSHL)
Products Industry AI-based drug discovery / AI-based drug development
  Industry 2 artificial intelligence (AI) / machine learning (ML)
Persons Person Pineda, Maria Luisa (Envisagenics 202211 CEO + Co-Founder)
  Person 2 Akerman, Martin (Envisagenics 202211 CTO + Co-Founder)
Region Region New York, NY
  Country United States (USA)
  Street 30-02 48th Avenue
Suites 140 and 150
  City 11101 Long Island City, New York, NY
    Address record changed: 2024-01-05
Basic data Employees n. a.
    * Document for »About Section«: Envisagenics, Inc.. (11/29/22). "Press Release: Envisagenics Announces Research Collaboration with Bristol Myers Squibb". New York, NY.
Record changed: 2023-07-10


Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Envisagenics Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top